EP1732548 - METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS [Right-click to bookmark this link] | Status | Patent maintained as amended Status updated on 28.07.2023 Database last updated on 24.04.2024 | Most recent event Tooltip | 28.07.2023 | Patent maintained (B2 publication) | published on 30.08.2023 [2023/35] | Applicant(s) | For all designated states Acorda Therapeutics, Inc. 420 Saw Mill River Road Ardsley, NY 10502 / US | [2013/11] |
Former [2006/51] | For all designated states Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10531 / US | Inventor(s) | 01 /
BLIGHT, Andrew, R. 10 Oskar Drive Mahopac, NY 10541 / US | 02 /
MARINUCCI, Lawrence 25 Bank Street Apartment 214H White Plains, NY 10606 / US | 03 /
COHEN, Ron 246 Harriman Road Irvington, NY 10533 / US | [2023/35] |
Former [2006/51] | 01 /
BLIGHT, Andrew, R. 10 Oskar Drive Mahopac, NY 10541 / US | ||
02 /
MARINUCCI, Lawrence 25 Bank Street Apartment 214H White Plains, NY 10606 / US | |||
03 /
COHEN, Ron 246 Harriman Road Irvington, NY 10533 / US | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2023/35] |
Former [2012/19] | Goodfellow, Hugh Robin, et al Carpmaels & Ransford One Southampton Row London WC1B 5HA / GB | ||
Former [2009/48] | Ouzman, Beverley Nicola Claire, et al Murgitroyd & Company Scotland House 165-169 Scotland Street Glasgow G5 8PL / GB | ||
Former [2006/51] | Ouzman, Beverley Nicola Claire, et al Murgitroyd and Company, 165-169 Scotland Street Glasgow G5 8PL / GB | Application number, filing date | 05732613.4 | 11.04.2005 | [2006/51] | WO2005US12427 | Priority number, date | US20040560894P | 09.04.2004 Original published format: US 560894 P | US20050102559 | 08.04.2005 Original published format: US 102559 | [2006/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2005099701 | Date: | 27.10.2005 | Language: | EN | [2005/43] | Type: | A2 Application without search report | No.: | EP1732548 | Date: | 20.12.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.10.2005 takes the place of the publication of the European patent application. | [2006/51] | Type: | B1 Patent specification | No.: | EP1732548 | Date: | 08.06.2011 | Language: | EN | [2011/23] | Type: | B9 Corrected patent specification | No.: | EP1732548 | Date: | 21.03.2012 | [2012/12] | Type: | B2 New European patent specification | No.: | EP1732548 | Date: | 30.08.2023 | Language: | EN | [2023/35] | Search report(s) | International search report - published on: | US | 23.03.2006 | (Supplementary) European search report - dispatched on: | EP | 07.05.2009 | Classification | IPC: | A61K31/44 | [2006/51] | CPC: |
A61K31/4409 (EP,US);
A61K31/435 (EP,US);
A61K31/44 (EP,US);
A61K9/20 (US);
A61P17/02 (EP);
A61P19/08 (EP);
A61P21/00 (EP);
A61P25/00 (EP);
A61P25/28 (EP);
A61P43/00 (EP)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2023/35] |
Former [2006/51] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | Extension states | AL | 09.10.2006 | BA | 09.10.2006 | HR | 09.10.2006 | LV | 09.10.2006 | MK | 09.10.2006 | YU | 09.10.2006 | Title | German: | VERFAHREN ZUR VERWENDUNG VON AMINOPYRIN-ZUSAMMENSETZUNGEN MIT VERZÖGERTER FREISETZUNG | [2010/45] | English: | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | [2006/51] | French: | UTILISATION DE COMPOSITIONS D'AMINOPYRIDINE A LIBERATION SOUTENUE | [2006/51] |
Former [2006/51] | VERFAHREN ZUR VERWENDUNG VON AMINOPYRIN-ZUSAMMENSETZUNG MIT VERZÖGERTER FREISETZUNG | Entry into regional phase | 09.10.2006 | National basic fee paid | 09.10.2006 | Search fee paid | 09.10.2006 | Designation fee(s) paid | 09.10.2006 | Examination fee paid | Examination procedure | 09.10.2006 | Amendment by applicant (claims and/or description) | 09.10.2006 | Examination requested [2006/51] | 27.08.2009 | Despatch of a communication from the examining division (Time limit: M04) | 16.10.2009 | Reply to a communication from the examining division | 26.10.2009 | Despatch of a communication from the examining division (Time limit: M04) | 05.03.2010 | Reply to a communication from the examining division | 30.03.2010 | Despatch of a communication from the examining division (Time limit: M02) | 12.04.2010 | Reply to a communication from the examining division | 12.11.2010 | Communication of intention to grant the patent | 17.03.2011 | Fee for grant paid | 17.03.2011 | Fee for publishing/printing paid | Divisional application(s) | EP11160247.0 / EP2377536 | EP11168901.4 / EP2422782 | EP11179067.1 / EP2460521 | EP21170762.5 / EP3922248 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 27.08.2009 | Opposition(s) | Opponent(s) | 01
07.03.2012
14.03.2012
ADMISSIBLE Synthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Benneker, Franciscus B. G., et al, et al Synthon BV Microweg 22 6545 CM Nijmegen / NL | 02
08.03.2012
23.03.2012
ADMISSIBLE neuraxpharm Arzneimittel GmbH Elisabeth-Selbert-Str. 23 40764 Langenfeld / DE Opponent's representative Königer, Karsten, et al, et al Harmsen Utescher Rechtsanwalts- und Patentanwaltspartnerschaft mbB Neuer Wall 80 20354 Hamburg / DE | [2023/27] |
Former [2013/22] | |||
Opponent(s) | 01
07.03.2012
14.03.2012
ADMISSIBLE Synthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Prins, Hendrik Willem, et al, et al Arnold & Siedsma Sweelinckplein 1 2517 GK The Hague / NL | ||
02
08.03.2012
23.03.2012
ADMISSIBLE neuraxpharm Arzneimittel GmbH Elisabeth-Selbert-Str. 23 40764 Langenfeld / DE Opponent's representative Königer, Karsten, et al, et al Harmsen Utescher Rechtsanwälte Patentanwälte Neuer Wall 80 D-20354 Hamburg / DE | |||
Former [2012/16] | |||
Opponent(s) | 01
07.03.2012
14.03.2012
ADMISSIBLE Synthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Prins, Hendrik Willem, et al, et al Arnold & Siedsma Sweelinckplein 1 2517 GK The Hague / NL | ||
02
08.03.2012
ADMISSIBLE neuraxpharm Arzneimittel GmbH & Co. KG Elisabeth-Selbert-Strasse 23 40764 Langenfeld / DE Opponent's representative Königer, Karsten Harmsen Utescher Rechtsanwälte Patentanwälte Neuer Wall 80 D-20354 Hamburg / DE | |||
Former [2012/15] | |||
Opponent(s) | 01
07.03.2012
ADMISSIBLE Synthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Prins, Hendrik Willem Arnold & Siedsma Sweelinckplein 1 2517 GK The Hague / NL | 16.04.2012 | Invitation to proprietor to file observations on the notice of opposition | 02.01.2013 | Reply of patent proprietor to notice(s) of opposition | 11.11.2013 | Date of oral proceedings | 19.12.2013 | Despatch of minutes of oral proceedings | 09.03.2021 | Despatch of a communication from the opposition division (Time limit: M02) | 16.03.2021 | Reply to a communication from the opposition division | 22.11.2021 | Despatch of a communication from the opposition division (Time limit: M02) | 01.02.2022 | Reply to a communication from the opposition division | 14.04.2022 | Despatch of a communication from the opposition division (Time limit: M02) | 20.06.2022 | Reply to a communication from the opposition division | 02.08.2022 | Despatch of a communication from the opposition division (Time limit: M02) | 08.02.2023 | Despatch of interlocutory decision in opposition | 18.02.2023 | Legal effect of interlocutory decision in opposition | 06.06.2023 | Despatch of communication that the patent will be maintained as amended | 26.07.2023 | Fee for printing new specification paid | Appeal following opposition | 27.02.2014 | Appeal received No. T0421/14 | 29.04.2014 | Statement of grounds filed | 03.09.2019 | Result of appeal procedure: maintenance in amended form | 17.02.2014 | Appeal received No. T0421/14 | 28.04.2014 | Statement of grounds filed | 03.09.2019 | Result of appeal procedure: maintenance in amended form | 02.09.2019 | Date of oral proceedings | 11.09.2019 | Minutes of the oral proceedings despatched | Fees paid | Renewal fee | 27.04.2007 | Renewal fee patent year 03 | 25.04.2008 | Renewal fee patent year 04 | 29.04.2009 | Renewal fee patent year 05 | 26.04.2010 | Renewal fee patent year 06 | 25.04.2011 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]IE82916 (ELAN CORP PLC) [X] 1-19* claim 1 *; | [X] - BEVER C T, "THE CURRENT STATUS OF STUDIES OF AMINOPYRIDINES IN PATIENTS WITH MULTIPLE SCLEROSIS", ANNALS OF NEUROLOGY, BOSTON, US, (19940101), vol. 36, ISSN 0364-5134, pages S118 - S121, XP000653261 [X] 1-19 * table 1 * DOI: http://dx.doi.org/10.1002/ana.410360728 | [X] - BEVER C T JR ET AL, "The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (19940601), vol. 44, no. 6, ISSN 0028-3878, pages 1054 - 1059, XP009115521 [X] 1-19 * see "Treatment" * | [X] - SCHWID S R ET AL, "Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (19970401), vol. 48, no. 4, ISSN 0028-3878, pages 817 - 821, XP009115522 [X] 1-19 * see "Procedure". * | [X] - VAN DIEMEN H A M ET AL, "THE EFFECT OF 4 AMINOPYRIDINE ON CLINICAL SIGNS IN MULTIPLE SCLEROSIS A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND CROSS-OVER STUDY", ANNALS OF NEUROLOGY, (1992), vol. 32, no. 2, ISSN 0364-5134, pages 123 - 130, XP002524401 [X] 1-19 * abstract * DOI: http://dx.doi.org/10.1002/ana.410320203 | International search | [X]EP0484186 (ELAN CORP PLC [IE]); | [X] - FUJIHARA ET AL, "The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis.", JOURNAL OF THE NEUROLOGICAL SCIENCES., (1988), vol. 159, pages 102 - 106, XP001151991 DOI: http://dx.doi.org/10.1016/S0022-510X(98)00143-9 | other | US8007826 | EP2377536 | US8663685 | - GOODMAN ANDREW D ET AL, "Placebo-controlled double-blinded dose ranging study of fampridine-SR in multiple sclerosis", NEUROLOGY, vol. 60, no. 5 Supp, (20030311), XP009154279 | - "Final Program, Abstract Listing and Meeting Information", ACTRIMS-ECTRIMS 2002, (20020918), XP055502446 | - Goodman A. D. ET AL, "P 308: PLACEBO-CONTROLLED DOUBLE-BLINDED DOSE RANGING STUDY OF FAMPRIDINE-SR IN MULTIPLE SCLEROSIS", Multiple Sclerosis, (20020000), pages S116 - S117, XP055502452 |